WebJan 31, 2024 · NEW YORK ─ Interpace Biosciences announced Friday that it is terminating a previously announced rights offering and standby purchase agreement with 3K Limited Partnership due to the likely adverse impact of a change in the Centers for Medicare & Medicaid Services' reimbursement policy for its thyroid tests.. The Parsippany, New … WebJan 28, 2024 · Tom Burnell, Interpace's President and CEO stated, "We are disappointed to terminate the rights offering due to the likely adverse impact of the change in CMS's policy but we are determined to ...
Interpace Biosciences Announces Record Date for Proposed
WebJan 28, 2024 · Tom Burnell, Interpace's President and CEO stated, "We are disappointed to terminate the rights offering due to the likely adverse impact of the change in CMS's … WebJan 31, 2024 · Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests PARSIPPANY, NJ, Jan. 28, 2024 - Interpace Biosciences, Inc.... December 26, 2024 focus boosting fruits
Interpace Biosciences Announces Record Date for Proposed
WebJan 3, 2024 · Under the terms of the Rights Offering, the Company will distribute non-transferable subscription rights to each holder of its common stock as well as to each holder of its ou WebJan 3, 2024 · PARSIPPANY, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced that it has set the record date for its proposed fully back-stopped $30 Million Rights Offering. Under the terms of the Rights Offering, the Company will distribute non-transferable … WebJan 29, 2024 · PARSIPPANY, NJ, Jan. 28, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX:IDXG) ("Interpace" or the "Company") a leader in enabling … focus books